• Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act. S.935 Fair Accountability and Innovative Research Drug Pricing Act. S.1250/H.R.5958 Drug Price Transparency for Consumers Act.
• Patent abuse issues. S. 150 Affordable Prescriptions for Patients Act of 2023. S. 79 Interagency Patent Coordination Act. S. 2780 Medication Affordability and Patent Integrity Act S. 142 Preserve Access to Affordable Generics and Biosimilars Act Joint USPTO-FDA Collaboration Initiatives. S. 2140 Patent Eligibility Restoration Act of 2023 S. 2220 PREVAIL Act S. 3583 A bill to address patent thickets. H.R. 6986 To address patent thickets.
• Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act.

Duration: November 1, 2023 to present

General Issues: Medicare/Medicaid, Copyright/Patent/Trademark, Pharmacy

Spending: about $40,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2023: House of Representatives, U.S. Senate